Get the Stockscreener App
7.29
2.02%
-0.15
Pre-market:
7.30
0.010
+0.14%
Alumis Inc stock is traded at $7.29, with a volume of 2.60M.
It is down -2.02% in the last 24 hours and down -68.35% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
See More
Previous Close:
$7.44
Open:
$7.43
24h Volume:
2.60M
Relative Volume:
1.08
Market Cap:
$943.58M
Revenue:
$8.40M
Net Income/Loss:
$-237.42M
P/E Ratio:
-3.7943
EPS:
-1.9213
Net Cash Flow:
$-377.03M
1W Performance:
-6.78%
1M Performance:
-68.35%
6M Performance:
-68.40%
1Y Performance:
+76.09%
1-Day Range:
$7.22
$7.45
1-Week Range:
$7.22
$8.14
52-Week Range:
$3.76
$31.35
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
7.29 | 943.58M | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff? - Stocktwits
(ALMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cantor Fitzgerald reiterates Alumis stock rating on oral therapy outlook By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Alumis stock rating on oral therapy outlook - Investing.com
Why is Alumis stock rallying today? By Investing.com - Investing.com India
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing - marketscreener.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com India
Alumis at Cantor conference: psoriasis strength, lupus setback - investing.com
Alumis at Cantor conference: psoriasis strength, lupus setback By Investing.com - Investing.com Canada
Alumis (NASDAQ: ALMS) director buys 986K shares, agrees to give back trade profit - Stock Titan
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - Yahoo Finance
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com Canada
Price-Driven Insight from (ALMS) for Rule-Based Strategy - Stock Traders Daily
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven DiseasesSlideshow (NASDAQ:ALMS) 2026-09-04 - Seeking Alpha
Alumis to Participate in Upcoming September Investor Conferences - The Manila Times
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - Yahoo Finance
Alumis stock downgraded at Guggenheim (ALMS:NASDAQ) - Seeking Alpha
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy - finance.yahoo.com
Guggenheim Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair? - Yahoo Finance
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints - Yahoo Finance
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Canada
Guggenheim downgrades Alumis stock rating after trial miss - investing.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure By Investing.com - Investing.com South Africa
Alumis (ALMS) Stock Slides As Momentum Traders Refocus On Fundamentals - timothysykes.com
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says - marketscreener.com
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating - marketscreener.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com India
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Australia
Wells Fargo cuts Alumis stock price target on SLE trial results By Investing.com - Investing.com South Africa
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues. - Pluang
Alumis plunges 57% after trial failure; Enovis falls 16% on robotics acquisition news - Pluang
Alumis shares plunge after lupus trial failure, but drug potential remains uncertain - Pluang
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside (NASDAQ:ALMS) - Seeking Alpha
Alumis Plunges 56% After Lupus Drug Fails Key Trial Goals - finance.biggo.com
Apple, Tesla, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Alumis’ TYK2 drug fails in key lupus study - BioPharma Dive
Alumis Shares Plummet 59% After Lupus Study Failure Wipes Out $1.67 Billion - TechStock²
Alumis stock tumbles 55% after lupus drug trial misses goals By Investing.com - Investing.com Nigeria
Alumis stock tumbles 55% after lupus drug trial misses goals - Investing.com India
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise - TradingView
Why Is Alumis Stock Falling Tuesday? - Benzinga
Alumis Announces Topline Phase 2b Results for Envudeucitinib in Systemic Lupus Erythematosus - Kalkine Media
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' - Endpoints News
Alumis falls after trial setback for lead drug (ALMS:NASDAQ) - Seeking Alpha
Why is Alumis stock collapsing today? By Investing.com - Investing.com Australia
Alumis Phase 2b lupus trial misses primary and secondary endpoints - Yahoo Finance
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):